



**University of Dundee**

**Cancer survivorship, excess body fatness and weight-loss intervention—where are we in 2020?**

Anderson, Annie; Martin, Richard M.; Renehan, Andrew G.; Cade, Janet; Copson, Ellen R.; Cross, Amanda J.

*Published in:*  
British Journal of Cancer

*DOI:*  
[10.1038/S41416-020-01155-2](https://doi.org/10.1038/S41416-020-01155-2)

*Publication date:*  
2020

*Document Version*  
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

*Citation for published version (APA):*

Anderson, A., Martin, R. M., Renehan, A. G., Cade, J., Copson, E. R., Cross, A. J., Grimmett, C., Keaver, L., King, A., Riboli, E., Shaw, C., Saxton, J. M. (2020). Cancer survivorship, excess body fatness and weight-loss intervention—where are we in 2020? *British Journal of Cancer*, 124, 1057-1065. <https://doi.org/10.1038/S41416-020-01155-2>

**General rights**

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

**Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

**Table 2 Range of core outcomes relevant in clinical trials of weight management**

Cancer type	Specific clinical setting	No of core measures	Description of core outcome sets
Breast cancer <sup>69</sup>	All treatments	27	<p><b>Survival and disease control:</b></p> <p>Overall survival; death attributed to breast cancer; recurrence-free survival</p> <p><b>Degree of health:</b></p> <p>Overall well-being; physical functioning; emotional functioning; cognitive functioning; social functioning; ability to work; anxiety; depression; insomnia; financial impact; pain; fatigue; sexual function; body image</p> <p><b>Patients treated with surgery and/or radiotherapy:</b></p> <p>Satisfaction with breast(s); arm symptoms; breast symptoms, lymphoedema</p> <p><b>Patients with systemic therapy:</b></p> <p>Vasomotor symptoms; peripheral neuropathy; vaginal symptoms; arthralgia</p> <p><b>Disutility of care:</b></p> <p>Reoperation owing to involved margins; severity of acute complications (based on the assessment of post operative outcome scores)</p>
Prostate cancer <sup>70</sup>	Localised	19	<p>12 apply to <b>all interventions</b>: death from prostate cancer, death from any cause, local disease recurrence, distant disease recurrence/metastases, disease progression, need for salvage therapy, overall quality of life, stress urinary incontinence, urinary function, bowel function, faecal incontinence, and sexual function.</p> <p>7 were <b>intervention-specific</b>: perioperative deaths (surgery), positive surgical margin (surgery), thromboembolic disease (surgery), bothersome or symptomatic urethral or anastomotic stricture (surgery), need for curative treatment (active surveillance), treatment failure (ablative therapy), and side-</p>

Colorectal cancer <sup>71</sup>	Surgery	12	<p>effects of hormonal therapy (hormone therapy).</p> <p><b>Oncological outcomes:</b> Long-term survival; cancer recurrence; resection margins</p> <p><b>Operative outcomes:</b> Anastomotic leak; perioperative survival; surgical site infection; stoma rates and complications; conversion to open operation (where appropriate)</p> <p><b>Quality of life:</b> Physical function; sexual function; faecal incontinence; faecal urgency</p>
---------------------------------	---------	----	--